News

Show
news from

SwanBio Evolves Leadership Team with Appointment of Executive Chair and Chief Operating Officer

SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for Adrenomyeloneuropathy

SwanBio Therapeutics Confirms Substantial Burden of Disease of Adrenomyeloneuropathy (AMN) in Both Men and Women

SwanBio Therapeutics Initiates First-in-Human Study of AAV Gene Therapy for Adrenomyeloneuropathy

SwanBio Presents Design of Innovative Natural History Study Aimed to Evolve Understanding of Adrenomyeloneuropathy and Inform Future Treatments

SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions

Load more

Search